Reuters logo
Lilly's Alimta combination cancer therapy fails trial
September 6, 2012 / 1:35 PM / in 5 years

Lilly's Alimta combination cancer therapy fails trial

Sept 6 (Reuters) - Eli Lilly and Co said a late-stage trial testing its lung cancer drug Alimta failed to meet the main study goal of improving overall survival of patients.

Patients on the trial, named Pointbreak, were given either a combination of Alimta and Roche Holding AG’s cancer drug Avastin along with chemotherapy, or just Avastin along with chemotherapy drugs.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below